03860nam 2200613 a 450 991087730500332120200520144314.01-282-34805-197866123480510-470-51539-20-470-51540-6(CKB)1000000000376023(EBL)470448(OCoLC)609849347(SSID)ssj0000305014(PQKBManifestationID)11259778(PQKBTitleCode)TC0000305014(PQKBWorkID)10285230(PQKB)11605647(MiAaPQ)EBC470448(EXLCZ)99100000000037602319970602d1997 uy 0engur|n|---|||||txtccrOligonucleotides as therapeutic agents /[editors, Derek J. Chadwick (Organizer) and Gail Cardew]Chichester ;New York Wiley19971 online resource (262 p.)Ciba Foundation symposium ;209Proceedings of the Symposium on Oligonucleotides as Therapeutic Agents, held at Ciba Foundation on 7-9 January 1997.0-471-97279-7 Includes bibliographical references and indexes.OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS; Contents; Participants; Introduction; Oligoncleotide analogues: an overview; Phosphorothioate oligodeox ynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry; Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays; Pharrnacokinetics of oligonucleotides in cell culture; Pharrnacokinetics of oligonucleotides; Controversies in the cellular pharmacology of oligodeox ynucleotides; Sequence-specific control of gene expression by antigene and clamp oligonucleotidesFirst- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinaseDifferential oligonucleotide activity in cell culture versus mouse models; Structure-activity relationships in cell culture; Progress in antisense therapeutics discovery and development; Oligonucleotide therapeutics for human leukemia; Therapeutic applications of catalytic antisense RNAs (ribozymes); Exogenous application of riboaymes for inhibiting gene expression; Efficient process technologies for the preparation of oligonucleotidesIn vivo production of oligodeoxyribonucleotides of specific sequences: application to antisense DNASummary; Index of contributors; Subject indexThe use of oligonucleotides as therapeutic agents rests upon their ability to interfere, in a sequence-specific manner, with the fundamental machinery of protein synthesis either by binding to the mRNAs transcribed from a gene or by binding directly to a target gene. This approach can be used not only for inhibition of the synthesis of host proteins but also of those required by invading pathogens. Potential therapeutic applications are enormous, ranging over hypertension, cardiovascular disease, autoimmune disease, vital and other parasitic infections (especially HIV), and cancer. This book dCiba Foundation symposium ;209.OligonucleotidesTherapeutic useCongressesAntisense nucleic acidsTherapeutic useCongressesOligonucleotidesTherapeutic useAntisense nucleic acidsTherapeutic use615/.31Chadwick Derek91632Cardew Gail857118Symposium on Oligonucleotides as Therapeutic Agents(1997 :Ciba Foundation)MiAaPQMiAaPQMiAaPQBOOK9910877305003321Oligonucleotides as therapeutic agents2013976UNINA